Clinical Trials · NCT06352424
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 23
- Start date
- Apr 2024
- Locations
- 1 site, Germany
- Primary endpoint
- Blood Oxygen Level Dependent (BOLD) signal changes following treatment with single dose of BI 1820237 alone, BI 456906 alone, and combination of BI 1820237 + BI 456906 versus placebo